237 related articles for article (PubMed ID: 27278257)
1. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
2. GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.
Xiong X; Zhang J; Li A; Dai L; Qin S; Wang P; Liu W; Zhang Z; Li X; Liu Z
Cancer Biol Ther; 2020; 21(3):213-222. PubMed ID: 31651209
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.
Pereira ASA; Amaral MS; Vasconcelos EJR; Pires DS; Asif H; daSilva LF; Morales-Vicente DA; Carneiro VC; Angeli CB; Palmisano G; Fantappie MR; Pierce RJ; Setubal JC; Verjovski-Almeida S
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006873. PubMed ID: 30365505
[TBL] [Abstract][Full Text] [Related]
5. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
6. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
9. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.
Ihira K; Dong P; Xiong Y; Watari H; Konno Y; Hanley SJ; Noguchi M; Hirata N; Suizu F; Yamada T; Kudo M; Sakuragi N
Oncotarget; 2017 Feb; 8(8):13509-13520. PubMed ID: 28088786
[TBL] [Abstract][Full Text] [Related]
10. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.
Yu T; Wang Y; Hu Q; Wu W; Wu Y; Wei W; Han D; You Y; Lin N; Liu N
Oncotarget; 2017 Nov; 8(58):98348-98359. PubMed ID: 29228694
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
12. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
Lv YF; Yan GN; Meng G; Zhang X; Guo QN
Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
17. The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.
Sasaki H; Setoguchi T; Matsunoshita Y; Gao H; Hirotsu M; Komiya S
Oncol Rep; 2010 Mar; 23(3):677-84. PubMed ID: 20127006
[TBL] [Abstract][Full Text] [Related]
18. Paternal genome rescues mouse preimplantation embryo development in the absence of maternally-recruited EZH2 activity.
Wang H; Paulson EE; Ma L; Ross PJ; Schultz RM
Epigenetics; 2019 Jan; 14(1):94-108. PubMed ID: 30661456
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic effect of enhancer of Zeste homolog 2 inhibitor GSK343 on periodontitis by regulating macrophage differentiation].
Zhongchao W; Liyuan F; Dan T; Cong Z; Shijun L
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):264-268. PubMed ID: 28675010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
